Zacks: Cellectis SA (NASDAQ:CLLS) Given $56.00 Average Target Price by Analysts

Shares of Cellectis SA (NASDAQ:CLLS) have been assigned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price target of $56.00 for the company and are anticipating that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also given Cellectis SA an industry rank of 73 out of 265 based on the ratings given to related companies.

A number of brokerages have commented on CLLS. Piper Jaffray reissued a “buy” rating on shares of Cellectis SA in a research note on Tuesday, November 17th. Zacks Investment Research raised Cellectis SA from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Tuesday, November 17th.

Shares of Cellectis SA (NASDAQ:CLLS) opened at 30.138 on Monday. Cellectis SA has a 52 week low of $23.52 and a 52 week high of $50.00. The stock’s 50 day moving average price is $31.35 and its 200-day moving average price is $32.26. The company’s market cap is $1.06 billion.

Cellectis SA (NASDAQ:CLLS) last issued its earnings results on Thursday, November 19th. The company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.33. Analysts expect that Cellectis SA will post ($1.00) EPS for the current year.

12 Month Chart for NASDAQ:CLLS

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (NASDAQ:CLLS) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Get a free copy of the Zacks research report on Cellectis SA (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Boeing Profit Drops on Lag in Commercial Deliveries
Boeing Profit Drops on Lag in Commercial Deliveries


Leave a Reply

 
© 2006-2017 The Vista Voice. Subscribe